Autoplaque vs AVIEW Lung Nodule CAD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

AVIEW Lung Nodule CAD

by Coreline Soft

AI Verdict

Autoplaque is specifically designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction. AVIEW Lung Nodule CAD primarily focuses on detecting and analyzing pulmonary nodules for lung cancer screening, but also includes coronary artery calcification scoring. While both offer AI-powered cardiac assessment from CT scans, Autoplaque specializes in detailed plaque and stenosis analysis, whereas AVIEW Lung Nodule CAD provides CAC scoring as part of a broader lung health screening.

Choose Autoplaque if…

Choose Autoplaque if your primary focus is on detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for cardiologists and radiologists seeking precise measurements for heart attack risk prediction and guiding treatment strategies based on specific plaque characteristics.

View Autoplaque →

Choose AVIEW Lung Nodule CAD if…

Choose AVIEW Lung Nodule CAD if you require a comprehensive AI-powered solution for analyzing chest CT scans, particularly for lung cancer screening and multi-condition assessment. This tool is best suited for radiologists who need to simultaneously detect and characterize pulmonary nodules, quantify emphysema, and score coronary artery calcification for a holistic patient evaluation.

View AVIEW Lung Nodule CAD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	AVIEW Lung Nodule CAD
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	On-premises and cloud environment
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW Lung Nodule CAD

Tool B offers more flexible deployment options, including cloud-based and virtualized solutions, which can enhance accessibility and integration into diverse clinical environments. Additionally, its automatic report generation based on Lung-RADS classification streamlines workflow and reduces manual effort. Tool A, while offering clinician review and editing, is limited to workstation-based deployment.

Clinical Value

AVIEW Lung Nodule CAD

While both tools are FDA-cleared and provide critical quantitative analysis, Tool B offers a broader clinical scope by simultaneously analyzing lung nodules, emphysema, and coronary artery calcification (the 'Big 3'). This comprehensive screening from a single CT scan provides greater multi-faceted clinical value compared to Tool A's focused analysis of coronary plaques and stenoses for heart attack risk prediction.

Pricing & Value

Tie

Neither tool publicly discloses its pricing, making a direct comparison of pricing and value impossible. While Tool B provides some context on typical pricing models for similar systems, this is not enough to determine a winner. Without specific cost information, it's impossible to assess which offers better value.

Enterprise Readiness

AVIEW Lung Nodule CAD

Tool B explicitly states HIPAA compliance and offers a wide array of deployment options, including cloud, hybrid, local, and virtualized solutions, which are crucial for seamless enterprise integration and scalability. Tool A, being workstation-based and lacking explicit HIPAA compliance or BAA information, presents more potential hurdles for large-scale enterprise adoption.

Innovation

AVIEW Lung Nodule CAD

Both tools leverage AI for advanced quantitative analysis in their respective fields. However, Tool B's 'Big 3' simultaneous analysis of lung nodules, emphysema, and coronary artery calcification from a single CT scan represents a significant innovation in integrated diagnostics. This multi-disease screening approach potentially offers a more holistic view of patient health risks and streamlines the diagnostic process.

Support & Docs

Tie

The provided structured facts do not contain any information regarding support or documentation for either Autoplaque or AVIEW Lung Nodule CAD. Without any available details, it is not possible to distinguish between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	AVIEW Lung Nodule CAD
Primary Clinical Focus	Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	Detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification.
Key Quantitative Analysis	AI-powered quantitative analysis of atherosclerotic plaque, measurement of luminal stenoses, measurement of vessel diameter and area.	3D nodule size and volume quantification, volume doubling time (VDT) calculation, quantitative emphysema analysis (LAA, emphysema index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores).
Target Anatomy/Pathology	Coronary plaques, luminal stenoses, coronary anatomy and pathology.	Pulmonary nodules, emphysema, coronary artery calcification.
Specialties Supported	Cardiology, Radiology	Cardiology, Pulmonology, Radiology
Automated Features	Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician).	Automatic report generation based on Lung-RADS classification, nodule matching for follow-up comparisons.

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and AVIEW Lung Nodule CAD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and differences in focus between Autoplaque and AVIEW Lung Nodule CAD?

Autoplaque is an FDA-cleared AI-powered software specifically designed for the quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. AVIEW Lung Nodule CAD is also FDA-cleared AI-powered software that assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and it offers comprehensive screening for lung cancer, COPD, and coronary artery calcification.

How do the cardiac analysis capabilities differ between the two tools?

Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque, including detection and characterization of coronary artery plaque, and measurement of luminal stenoses. AVIEW Lung Nodule CAD offers Coronary Artery Calcification (CAC) scoring, including Agatston, volume, and mass scores, as part of its simultaneous analysis of lung nodules, emphysema, and CAC.

Does either tool offer analysis beyond cardiac structures?

Yes, AVIEW Lung Nodule CAD provides AI-based pulmonary nodule detection (3-20 mm), classification (solid, part-solid, non-solid), and 3D nodule size and volume quantification, along with quantitative emphysema analysis. Autoplaque is specifically designed for coronary plaque and stenosis analysis.

What specific quantitative measurements and reporting features do these tools provide?

Autoplaque offers automated vessel, plaque, and lumen segmentation (reviewable and editable by a clinician), and measurement of vessel diameter and area, including calcified and non-calcified plaque volumes and stenosis percentage. AVIEW Lung Nodule CAD provides 3D nodule size and volume quantification, automatic report generation based on Lung-RADS classification, nodule matching and volume doubling time (VDT) calculation for follow-up comparisons, and Agatston, volume, and mass scores for CAC.